

University of Massachusetts Medical School

**eScholarship@UMMS**

---

GSBS Student Publications

Graduate School of Biomedical Sciences

---

2008-09-26

## Viral infection: a potent barrier to transplantation tolerance

David M. Miller

*University of Massachusetts Medical School*

*Et al.*

**Let us know how access to this document benefits you.**

Follow this and additional works at: [https://escholarship.umassmed.edu/gsbs\\_sp](https://escholarship.umassmed.edu/gsbs_sp)



Part of the [Immunity Commons](#), and the [Medicine and Health Sciences Commons](#)

---

### Repository Citation

Miller DM, Thornley TB, Greiner DL, Rossini AA. (2008). Viral infection: a potent barrier to transplantation tolerance. GSBS Student Publications. <https://doi.org/10.1155/2008/742810>. Retrieved from [https://escholarship.umassmed.edu/gsbs\\_sp/1562](https://escholarship.umassmed.edu/gsbs_sp/1562)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Student Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

## Review Article

# Viral Infection: A Potent Barrier to Transplantation Tolerance

David M. Miller,<sup>1</sup> Thomas B. Thornley,<sup>1</sup> Dale L. Greiner,<sup>1</sup> and Aldo A. Rossini<sup>1,2</sup>

<sup>1</sup> Division of Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA

<sup>2</sup> Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA

Correspondence should be addressed to Aldo A. Rossini, aldo.rossini@umassmed.edu

Received 8 April 2008; Accepted 26 June 2008

Recommended by Eiji Matsuura

Transplantation of allogeneic organs has proven to be an effective therapeutic for a large variety of disease states, but the chronic immunosuppression that is required for organ allograft survival increases the risk for infection and neoplasia and has direct organ toxicity. The establishment of transplantation tolerance, which obviates the need for chronic immunosuppression, is the ultimate goal in the field of transplantation. Many experimental approaches have been developed in animal models that permit long-term allograft survival in the absence of chronic immunosuppression. These approaches function by inducing peripheral or central tolerance to the allograft. Emerging as some of the most promising approaches for the induction of tolerance are protocols based on costimulation blockade. However, as these protocols move into the clinic, there is recognition that little is known as to their safety and efficacy when confronted with environmental perturbants such as virus infection. In animal models, it has been reported that virus infection can prevent the induction of tolerance by costimulation blockade and, in at least one experimental protocol, can lead to significant morbidity and mortality. In this review, we discuss how viruses modulate the induction and maintenance of transplantation tolerance.

Copyright © 2008 David M. Miller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## 1. INTRODUCTION

Organ transplantation in the clinic became a reality in 1954 when Merrill, Murray, and Harrison performed the first successful human vascular organ graft, a kidney transplant [1, 2]. However, the donor and recipient were monozygotic twins, obviating the need for immunosuppression for organ graft survival. With the development of immunosuppressive regimens, the same group 5 years later performed the first kidney allograft transplantation between unrelated individuals; that graft survived for 20 years [3]. Although successful graft survival was achieved, it rapidly became clear that all immunosuppressive drugs, even the newer generations of immunosuppressive regimens, are toxic [4, 5]. Immunosuppressive drugs are also known to increase the risk of infection and neoplasia [6, 7], and their associated side effects often lead to patient noncompliance [8]. Since most patients eventually reject transplanted allografts either acutely or through a process of chronic rejection [9–11], these deleterious side effects make organ transplantation a therapy in which the risk/benefit ratio must be carefully weighed.

To overcome issues associated with chronic immunosuppression, investigators have focused on approaches that lead to the induction of tolerance to transplanted organ allografts [12]. Operationally, transplantation tolerance is defined as the survival of a donor allogeneic graft in the absence of immunosuppression. Most transplantation tolerance induction protocols take advantage of information resulting from studies on the natural mechanisms by which the immune system prevents self-reactivity and autoimmune disease. Two major forms of natural tolerance have been identified: central tolerance and peripheral tolerance.

## 2. CENTRAL TRANSPLANTATION TOLERANCE

In 1953, Peter Medawar et al. obtained the first experimental evidence that the establishment of allogeneic hematopoietic chimerism leads to the induction of central tolerance and permits permanent acceptance of skin allografts [13]. Inspired by the work done in freemartin cattle by Owen in 1945 [14] and the clonal selection theory subsequently proposed by Burnet and Fenner [15], Medawar demonstrated

in mice that the transfer of allogeneic hematopoietic cells in utero could induce tolerance to skin transplanted from the original donor later in life [13].

Medawar's observation led Main and Prehn to experimentally induce hematopoietic chimerism by treating mice with whole-body irradiation (WBI) and allogeneic bone marrow cells, followed by transplantation with donor-strain-matched skin allografts [16]. This protocol successfully induced tolerance to skin allografts, conclusively linking the establishment of hematopoietic chimerism with subsequent allograft survival. However, despite the long-term survival of skin allografts on mice treated with WBI and allogeneic bone marrow, animals eventually develop lethal graft-versus-host disease (GVHD), a reaction where passenger leukocytes in the donor bone marrow or graft mount an immune response against the host. Therefore, modern conditioning protocols to induce central tolerance have been designed to address the common objectives of (1) establishing hematopoietic chimerism using a relatively benign preconditioning protocol that (2) prevents the development of GVHD.

Despite these common objectives, modern conditioning regimens can differ quite significantly in their methodology. In preclinical models of hematopoietic chimerism, conditioning regimens span the spectrum from myeloablative protocols, which often entail lethal irradiation and subsequent stem cell rescue, to noncytoreductive treatments that do not require irradiation, for example, costimulation blockade [17–19]. Between these two extremes are protocols that significantly weaken the recipient's immune system through selective antibody-mediated elimination of specific immune populations (e.g., CD4<sup>+</sup> and CD8<sup>+</sup> T cells) coupled with targeted irradiation (e.g., thymic irradiation) [20]. These latter protocols are often considered nonmyeloablative. In clinical trials, successful nonmyeloablative approaches have recently been described [21, 22]. Stable renal allograft function in recipients for as long as five years after complete withdrawal of immunosuppressive drugs was observed in recipients in which hematopoietic chimerism was established [21, 22]. These reports document that in humans, as in rodents, establishment of hematopoietic chimerism is a robust approach for the development of central tolerance and the permanent survival of donor-specific allografts.

### 3. PERIPHERAL TRANSPLANTATION TOLERANCE

The second major form of tolerance is peripheral tolerance. Different from central tolerance in which hematopoietic chimerism leads to the clonal deletion of antigen-specific cells during development, peripheral tolerance targets pre-existing cells that have already been generated. To induce tolerance in this population, fundamental insights into how naive antigen-specific T cells become activated have led to protocols designed to prevent this process. Naive T cell activation is initiated by the interaction of the antigen-specific T cell receptor (TCR) with a peptide presented by the MHC. This interaction conveys specificity leading to the activation of only antigen-specific T cells. This signal

is often termed as “signal 1” (Figure 1). Following TCR-peptide/MHC ligation, a T cell then receives a number of costimulatory signals [23–25]. A key costimulatory signal in this pathway that permits the activated naive T cells to become functional effector/memory T cells is provided by CD28-CD80/86 interaction [26], which has often been referred to as “signal 2.” In early studies, it was shown in vitro that T cells that receive signals through their TCR in the absence of engagement of the CD28-CD80/86 costimulation pathway became nonresponsive, a state of T cell nonresponsiveness often referred to as anergy [12, 27]. Following induction of signal 2, cytokines are produced that impart the final signal for T cell activation, and this is termed as “signal 3” [24, 28, 29]. Although these three critical signals are required for the full activation of T cells, additional signals such as those derived from CD40-CD154 interaction can have potent effects on the activation of naive T cells (Figure 1).

The existence of a comparable in vivo state of T cell nonresponsiveness has been debated for years until it was independently shown to exist by Ohashi et al. [30] and Oldstone et al. [31] using two very similar experimental systems. These investigators generated double-transgenic mice that expressed (1) lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) [30] or nucleoprotein (NP) [31] under the control of the rat insulin promoter, and (2) a transgenic TCR that recognizes a peptide from the transgenic LCMV protein. In unmanipulated mice, the transgenic T cells migrate from the thymus into the peripheral tissues and encounter their cognate antigen, but they remain nonresponsive to islets expressing GP or NP. However, LCMV infection reverses this state of nonresponsiveness, leading to a diabetic phenotype resulting from the destruction of pancreatic islets expressing the transgenic protein [30, 31]. These data support a mechanism where the LCMV-reactive T cells in naive mice encounter antigen in the absence of costimulation and become nonresponsive (tolerant), and further show that environmental perturbation can break this nonresponsive state. This model serves as the conceptual basis for the induction of peripheral transplantation tolerance, where the in vivo disruption of the costimulatory process—referred to as costimulation blockade—leads to the induction of tolerance in an antigen-specific manner [12].

Costimulation blockade therapies can target several different steps in the process of T cell activation. However, the CD40-CD154 pathway linking signal 1 to signal 2 has been identified to be a critical step in the activation of naive T cells. Anti-CD154 mAb blocks the interaction between CD154 on the T cell and CD40 on the APC [32, 33], and prevents the differentiation between naive T cells and effector/memory T cells [33] (Figure 1).

In peripheral tolerance induction protocols, anti-CD154 monotherapy significantly improves islet [34] and cardiac [35] allograft survival in mice and islet allograft survival in nonhuman primates [36–39]. In combination with a donor-specific transfusion (DST), anti-CD154 monoclonal antibody (mAb) induces permanent islet [34] and prolonged skin [40] allograft survival in mice. DST provides selective




FIGURE 1: *Costimulation blockade*. Activation of a T cell involves a series of interactive steps with an APC. The first signal imparts antigen specificity and commences when the TCR engages the antigen/MHC complex presented by the APC. This signal is commonly referred to as “signal 1.” In subsequent steps, the T cell receives a number of costimulatory signals, including those following interaction of CD154 on T cells with CD40 on APCs, which matures the APC to upregulate expression of CD80/86. The interaction of CD28 with CD80/86 is termed as “signal 2” and activates APCs to secrete cytokines, which provide the final activation signals to the T cell; this step is commonly referred to as “signal 3.” Protocols based on costimulation blockade can prevent T cell activation by targeting steps in the T cell activation cascade. Anti-CD154 mAb blocks the interaction between CD154 and CD40, and prevents the APC from upregulating CD80/86, blocking full APC activation. This prevents the secretion of proinflammatory cytokines, thus depriving the T cell of signal 3. As a result of costimulation blockade, the T cell does not develop an activated phenotype, and consequently becomes nonresponsive (tolerant) to allogeneic antigens.

activation of the alloantigen-specific T cells, and we have shown that the subsequent blockade of costimulation by anti-CD154 mAb leads to selective depletion of only the specific alloantigen-reactive CD8<sup>+</sup> T cells [41, 42]. Another reagent, CTLA4-Ig, binds to the costimulatory molecules CD80/86 on the APC. This blocks its interaction with CD28 on the T cell, preventing signal 2. CTLA4-Ig monotherapy induces the survival of xenogeneic islets [43] and allogeneic cardiac grafts [44]. Not surprisingly, the combination of anti-CD154 mAb and CTLA4-Ig has shown great potential in prolonging skin and cardiac allograft survival in mice [45].

Effective as a peripheral tolerance induction protocol, costimulation blockade protocols based on blockade of the CD40-CD154 pathway have also been used to establish hematopoietic chimerism leading to the generation of central tolerance [17–19]. By establishing multilineage hematopoietic chimerism, these noncytoreductive protocols have proven to promote robust transplantation tolerance to a variety of solid-organ allografts across fully allogeneic barriers when transplanted several weeks after bone marrow transplantation (BMT) [17, 18] or being concurrent with BMT [19, 46]. Furthermore, because donor-reactivity against the host is dependent on the CD40-CD154 pathway [47], costimulation blockade effectively establishes hematopoietic chimerism in the absence of GVHD [17, 18].

#### 4. VIRUS INFECTION AND TRANSPLANTATION TOLERANCE

As costimulation blockade protocols move closer to clinical reality, there is concern that virus infection during tolerance induction may (1) induce tolerance to the virus, (2) prevent the induction or maintenance of tolerance to the

organ allograft, or (3) increase risk to the host. Viruses are known to stimulate innate immunity by activating various pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs) [48]. Activation of innate immunity by virus infection leads to the modulation of adaptive immunity, and it has been shown to impair transplantation tolerance induction and allograft survival [49–57].

For example, infection with LCMV before [54], at the time of [51, 56], or shortly after costimulation blockade for the induction of peripheral tolerance [57] impairs allograft survival. Mice treated with costimulation blockade rapidly reject skin allografts if they are infected with LCMV shortly after skin transplantation [57]. Interestingly, this effect appeared to be virus-specific, as infection with vaccinia virus (VV) and murine cytomegalovirus (MCMV) did not engender allograft rejection [57]. Furthermore, skin allograft survival is significantly shortened in LCMV-immune mice treated with a peripheral tolerance induction protocol consisting of DST and anti-CD154 mAb combination therapies [54]. Additionally, TLRs and their proinflammatory role in responding to infection and ischemia are being increasingly seen as a serious obstacle to solid-organ transplantation [58–60].

Barriers to the induction of hematopoietic chimerism and establishment of central tolerance in the setting of viral infection have also been reported. Anti-CD154 mAb, CTLA4-Ig, and busulfan treatment fails to induce bone marrow chimerism and tolerance to skin allografts in the setting of multiple viral infections [53]. Moreover, using a nonmyeloablative protocol where anti-CD154 mAb treatment was coupled with sublethal irradiation, Forman et al. observed that infection with LCMV on the day of BM transplantation not only resulted in allograft rejection but also




FIGURE 2: *Pathogen recognition systems.* The innate immune system senses viral pathogens by recognizing distinct pathogen-associated molecular patterns (PAMPs) using various pattern recognition receptors (PRRs). Two of the best-characterized virus-sensing PRRs include member of the Toll-like receptors (TLRs) and retinoic acid inducible gene-I- (RIG-I-) like receptors (RLRs) families. These PRRs couple the recognition of viral PAMPs to the induction of proinflammatory cytokines through various signaling cascades. The cytosolic RNA helicase receptors MDA5 and RIG-I initiate the cascade by recruiting the Cardif/TBK1 complex after sensing viral RNA. This activates the kinase TBK1 to phosphorylate interferon regulatory factor (IRF)-3 and IRF7, resulting in their nuclear translocation and the transcription of IFN $\alpha/\beta$ . The cell surface receptor TLR4, in partnership with CD14, couples the recognition of respiratory syncytial virus fusion protein [78] to cytokine induction by signaling through the MyD88-dependent as well as the MyD88-independent pathways. The endosomal TLRs, TLR7, TLR8, and TLR9 also signal through MyD88 to activate inflammatory cytokines such as TNF, IL-6, and IFN- $\alpha/\beta$ . The other endosomal TLR (TLR3) signals through the MyD88-independent pathway via the TIR domain-containing adaptor molecule TRIF. Via TRIF, TLR3 signaling can activate NF- $\kappa$ B using TRAF6, and in addition, can induce type I IFN expression probably via TRAF3, TBK1, and IRF3.

proved lethal to the recipient [55]. Interestingly, conditioned recipients that were infected and given syngeneic BM grafts did not die. Recipients of allogeneic BM died by a type I interferon- (IFN-) dependent mechanism, whereas mice deficient in the type I IFN receptor survived. The recent deaths of a cluster of human transplant recipients of LCMV-infected organs make this finding particularly relevant to the

safety and efficacy of tolerance induction protocols based on costimulation blockade [61, 62].

## 5. INNATE IMMUNE ACTIVATION BY VIRUS INFECTION

It has been shown that mice infected with LCMV concurrent to costimulation blockade treatment [56, 63] or persistently






FIGURE 3: *Bystander activation of alloreactive T cells by “virus-licensed” APCs.* Upon viral infection, detection of pathogen-associated molecular patterns by PRRs can stimulate the production of inflammatory cytokines such as IFN- $\alpha/\beta$ , TNF- $\alpha$ , and IL-6. These cytokines activate alloantigen-processing APCs in a paracrine or autocrine fashion to upregulate MHC classes I and II, as well as costimulatory molecules, such as CD80 and CD86. The heightened expression of costimulatory molecules elicits the proliferation and differentiation of alloreactive T cells.

infected with LCMV clone 13 prior to costimulation blockade treatment [52] rapidly reject skin allografts. In a transgenic TCR model, LCMV prevents the deletion of alloreactive CD8<sup>+</sup> T cells that is ordinarily induced by costimulation blockade [56, 63]. In this same model system, injection of a TLR agonist similarly prevents the deletion of host alloreactive CD8<sup>+</sup> T cells which are required for skin allograft rejection [64].

Surprisingly, the TLR4 agonist LPS impairs CD8<sup>+</sup> T cell deletion and shortens skin allograft survival by activating host cells [64] rather than donor cells [64, 65], even though the transgenic CD8 T cells recognize donor antigen via the direct pathway. Furthermore, LPS required the expression of the adaptor molecule myeloid differentiation primary response gene-88 (MyD88) on the recipient to shorten allograft survival [65, 66]. These findings are consistent with clinical data suggesting that TLR4 polymorphisms on the host, but not the donor, correlate with allograft survival [67]. Together, these data suggest that TLR activation induces a soluble mediator that augments host T cell activation, perhaps through a process of bystander activation (see below).

Numerous cytokines are reported to be important in the activation of CD8<sup>+</sup> T cells, including IL-12 [29], TNF $\alpha$  [68, 69], and IFN- $\alpha/\beta$  [70]. While IL-12 and TNF $\alpha$  are dispensable for shortened allograft survival induced by LPS in costimulation blockade treatment protocols [64], IFN- $\alpha/\beta$  has been reported to be absolutely essential for LPS to prime CTLs and induce allograft rejection [65]. Type I IFNs also proved indispensable for allograft rejection mediated by the

dsRNA mimetic and TLR3 agonist poly I:C [65]. Emerging data suggest that IFN- $\alpha/\beta$  can be induced by viruses through a growing number of pathogen recognition receptor systems [71–74]. Thus the induction of IFN- $\alpha/\beta$  by virus infection or TLR ligation has emerged as an important obstacle to the establishment of peripheral transplantation tolerance as well as to the maintenance of self-tolerance [75].

## 6. SIGNALING PATHWAYS INVOLVED IN INNATE IMMUNE CELL ACTIVATION BY VIRUS INFECTION

How does virus-mediated activation of innate immunity lead to the production of IFN- $\alpha/\beta$ ? At present, the two best-characterized IFN- $\alpha/\beta$ -inducing viral recognition systems are members of the TLR and the retinoic acid inducible gene-I- (RIG-I-) like receptor (RLR) families (Figure 2). These receptors are activated by sensing viral nucleic acids either in the cytosol (RLR) or in endosomes (TLR) of cells [76]. Cytosolic receptors that detect nucleic acids upon viral infection are expressed ubiquitously by nucleated cells, while endosomal receptors, which detect viral particles that are engulfed from outside rather than from direct infection, are expressed in specialized cells of the innate immune system such as macrophages and dendritic cells [77].

Cytosolic RLRs, exemplified by the proteins RIG-I and melanoma differentiation factor-5 (MDA5), recognize double stranded RNA (dsRNA) located in the cytosol following replication by an RNA virus, or infection by




FIGURE 4: *Modulation of regulatory mechanisms by virus infection.* Regulatory T cells play a crucial role in transplantation tolerance to allogeneic organs. Regulatory mechanisms that prevent immune attack on allogeneic tissues may be compromised in the setting of viral infection by at least two mechanisms. Release of inflammatory cytokines by virus-infected cells can prevent the differentiation of uncommitted naïve CD4<sup>+</sup> T cells into Tregs. Naïve CD4<sup>+</sup> T cells can differentiate into regulatory T cells in the presence of TGF- $\beta$ . However, in the presence of TGF- $\beta$  and proinflammatory cytokines such as IL-6, and perhaps IL-21, naïve T cells can be skewed to turn into effector T cells such as the IL-17-producing TH17 cells. In a separate mechanism, release of cytokines such as IL-6 by infected APCs can render alloreactive effector cells refractory to suppression by regulatory T cells.

a dsRNA-genome virus, through interaction with their helicase domains [48]. RLRs contain a caspase recruitment domain (CARD) [72] which links detection of viral dsRNA to transcription of IFN- $\alpha/\beta$  by forming homotypic interactions with the CARD-containing molecule interferon- $\beta$  promoter stimulator (IPS-1, also known as mitochondrial antiviral signaling protein (MAVS), CARD adaptor inducing IFN- $\beta$  (CARDIF), and virus-induced signaling adaptor (VISA)) [79–82]. Activation of IPS-1 triggers members of the I $\kappa$ B kinase (IKK) family, specifically TANK-binding kinase 1 (TBK-1) and IKK $\epsilon$  (also known as inducible I $\kappa$ B kinase, IKK-i), to phosphorylate and activate interferon regulatory factor (IRF)-3 and/or IRF7 [83–88]. Once activated, IRF3 and IRF7 translocate to the nucleus and bind to interferon-

stimulated response elements (ISREs) to induce the expression of IFN- $\alpha$  and IFN- $\beta$ , as well as other IFN-inducible genes [48, 89, 90].

It has recently been recognized that cytoplasmic sensing of DNA can also trigger IFN- $\alpha$  and IFN- $\beta$  production [91–93]. This pathway is thought to intersect with the RIG-I and MDA5 pathways at the level of TBK-1 and IKK-I [91], and it requires IRF3 for IFN- $\alpha/\beta$  induction [92]. A candidate cytosolic recognition receptor that senses and is activated by DNA has been described [94]. This receptor, known as DNA-dependent activator of IFN-regulatory factors (DAI), was reported to induce type I IFN upon recognition of bacterial and mammalian as well as viral DNAs [94].




FIGURE 5: *Heterologous immunity; cross-reactivity between viral and allogeneic antigens.* Unlike the very small proportion of naive T cells that can respond to any given pathogen (reported to be  $\sim 1:200\,000$ ), the frequency of T cells that directly recognize allogeneic antigens, such as MHC, is thought to be within 1:100–1:10. A proportion of those TCRs that recognize alloantigens, therefore, may have arisen as a result of virus infection that induces virus-specific T cells that cross-react with allo-MHC. Activation of these T cells may result in the recognition of MHC molecules found on donor tissues, such as the endothelium of transplanted organs, precipitating allograft rejection.

With the exception of TLR4, all known TLRs that induce type I IFN recognize nucleic acids, and are found in the endosomal compartment of cells. These include TLR3, TLR7, TLR8, and TLR9. Unlike the cytoplasmic nucleic acid receptors, the cellular distribution of endosomal TLRs is much more restricted. TLR7 and TLR9, which recognize ssRNA [95, 96] and unmethylated DNA that contain CpG motifs [97], respectively, are expressed highly on both conventional (cDC) and plasmacytoid (pDC) dendritic cells. However, they can also be expressed on other hematopoietic cells, including B cells [98, 99]. TLR3, which recognizes dsRNA [71], has a broader distribution than TLR7 and TLR9, and can be found on nonhematopoietic cells such as astrocytes and epithelial cells of the cervix, airway, uterus, vagina, intestine, and cornea [76, 98–100]. Its expression, however, is thought to be highest in cDCs [76, 100].

Similar to the other non-IFN- $\alpha/\beta$ -inducing TLRs, TLR3, 7, 8, and 9 are capable of activating both NF- $\kappa$ B and MAPK cascades and triggering the transcription of scores of proinflammatory cytokines and chemokines [76, 99, 100]. However, the endosomal TLRs are also capable of signaling through additional cascades, which results in the expression of type I IFNs. Recognition of dsRNA by TLR3 results in

the activation of the adaptor molecule Toll/interleukin-1 receptor (TIR) domain-containing adaptor protein inducing IFN- $\beta$  (TRIF) [101]. TRIF interacts with tumor necrosis factor receptor-associated factor (TRAF)-3 to activate TBK1 [88] and, as described above, leads to the activation of IRF3 and IRF7 and induction of type I IFN. In contrast, the coupling of TLR7 and TLR9 to IFN- $\alpha/\beta$  production involves the adaptor molecule MyD88 [97, 102]. Following recognition of either ssRNA or unmethylated DNA, a large complex consisting of MyD88, TRAF3, TRAF6, IL-1 receptor-associated kinase (IRAK)-4, IRAK-1, IKK- $\alpha$ , and IRF-7 is recruited to the TLR [48, 87, 88, 103–105]. Following recruitment of the complex, cytokines downstream of NF- $\kappa$ B are stimulated, and type I IFN expression is induced in an osteopontin (OPN) [106] and IRF7-dependent fashion [48, 89]. Interestingly, stimulation of TLR7 and TLR9 in cDCs is capable of inducing the expression of cytokines that are downstream of the NF- $\kappa$ B pathway, such as IL-6 and IL-12. However, only pDCs are capable of producing IFN- $\alpha$  in response to ssRNA and CpG-containing DNA [76]. As exemplified by the multitude of signaling pathways by which TLRs can activate innate immunity, it is clear that virus or microbial infection has multiple ways to active innate



immunity and modulate the adaptive immune system during tolerance induction.

## 7. MECHANISMS OF VIRUS-MEDIATED MODULATION OF TRANSPLANTATION TOLERANCE

There are multiple mechanisms by which virus infection or TLR agonists may modulate tolerance induction and allograft survival. We will focus on three potential mechanisms. First, virus infection can mature APCs to prime non-cross-reactive T cells, a process called bystander activation [107, 108]. Second, virus infection may stimulate innate immune cells to produce cytokines that suppress tolerance-promoting regulatory T cells [109]. Third, virus infection may lead to the generation of virus-specific T cells that can cross-react with alloantigens, a phenomenon known as heterologous immunity [110].

### 7.1. Bystander activation

A mechanism by which virus infection may modulate tolerance induction is through bystander activation. As described above, virus infection activates innate immunity, and is able to mature APCs to “license” them to activate non-cross-reactive T cells. CD4<sup>+</sup> T cells are known to play a pivotal role in the licensing of antigen-presenting cells (APCs) [111]. The intercourse between antigen-specific CD4<sup>+</sup> T cells and antigen-presenting APCs is thought to be crucial for the generation of a full immune response. In the setting of viral infection, virus-specific CD4<sup>+</sup> T cells facilitate the maturation of virus-presenting APCs via CD154-CD40 interactions. Consequently, the APC is stimulated to upregulate costimulatory molecules, as well as to secrete proinflammatory cytokines. These molecules then feed back on the T cell, stimulate it to become fully activated, and release additional inflammatory cytokines and growth factors. Allospecific T cells that have encountered cognate alloantigen can be activated in this inflammatory milieu even if they do not cross-react with viral antigens. This process is traditionally referred to as bystander activation [111].

Viruses have also been shown to mature APCs independently of the normally required CD154-CD40 interaction. LCMV infection stimulates the upregulation of MHC classes I and II, CD40, CD80, and CD86 in the presence of CTLA-4-Ig and anti-CD154 mAb [51]. The molecular mechanisms that govern this process have not been fully elucidated; however, the induction of type I IFNs by virus-infected APCs is a likely candidate. IFN- $\alpha/\beta$  is known to directly induce the maturation of immature DCs, and it results in the upregulation of MHC and costimulatory molecules [112, 113]. Given that pDCs can produce up to a thousand-fold more type I IFN than other cells [113, 114], we propose that viral detection by pDCs triggers the release of IFN- $\alpha/\beta$  that can in turn act in a paracrine or autocrine fashion to mature alloantigen-presenting APCs (Figure 3). Thus, these “IFN- $\alpha/\beta$ -licensed” alloantigen-presenting APCs could directly stimulate alloreactive T cells, even in the presence of costimulation blockade.

### 7.2. Regulatory cell suppression

The induction and maintenance of CD4<sup>+</sup> regulatory T cells (Tregs) are essential to allograft survival [115–117]. Therefore, a second mechanism by which viruses could impair tolerance induction is through modulation of the generation or activity of this important T cell subset. In addition to priming cells through an IFN- $\alpha/\beta$ -dependent mechanism, TLR activation also prevents the intra-graft recruitment of regulatory T cells in an MyD88-dependent manner [66]. This observation extended earlier work showing that the MyD88 pathway plays an important role in the rejection of minor antigens [118] and cardiac allografts [119].

IL-6 is an MyD88-dependent cytokine that has emerged as a candidate mediator for impairing regulatory T cell generation and function; its production is diminished in untreated [119]—as well as LCMV-infected [120]—mice deficient in MyD88. CD4<sup>+</sup> T cells develop a FoxP3<sup>+</sup> regulatory T cell phenotype when they are activated in the presence of TGF- $\beta$ . However, when CD4<sup>+</sup> T cells are activated in the presence of TGF- $\beta$  and IL-6, this regulatory phenotype is suppressed and the cells develop a proinflammatory TH17 cell phenotype [121] (Figure 4). Therefore, virus infection may precipitate allograft rejection by preventing the generation of Tregs following costimulation blockade and instead favor development of proinflammatory effector T cells.

IL-6 has also been shown to be important in regulating antigen-specific adaptive immune responses via additional mechanisms. Pasare et al. demonstrated that microbial induction of the TLR pathway on DCs enabled effector T cells to overcome suppression by CD4<sup>+</sup>CD25<sup>+</sup> regulatory cells [122] (Figure 4). They reported that secretion of soluble mediators (principally IL-6) by TLR-activated DCs could render effector T cells refractory to Treg-mediated regulation, permitting activation of antigen-specific T cells in the presence of regulatory T cells. Hence, virus infection may trigger allograft rejection by compromising key regulatory mechanisms such as preventing the generation of regulatory T cells by costimulation blockade as well as by enabling alloreactive T cells to escape Treg-mediated suppression.

### 7.3. Heterologous immunity

The classic view of clonal T cell activation is that one TCR interacts with one cognate antigen. However, we now understand that TCR binding is degenerate, and can recognize multiple related and unrelated antigens. The ability of an antigen-specific T cell to cross-react with multiple antigens, known as heterologous immunity [110], can influence immunodominance, protective immunity, and immunopathology during subsequent viral infections [110, 123, 124].

In studies of peripheral tolerance induction, of particular interest to transplant scientists is the observation that virus-specific T cells cross-react with alloantigens (Figure 5) [125, 126]. Yang et al. have reported that acute infection with VV, MCMV, or arena viruses LCMV and pichinde virus (PV) resulted in the spontaneous generation of cytotoxic

lymphocytes (CTLs) with cytolytic activity towards allogeneic cells [127, 128]. These results were further supported by Nahill and Welsh [126], who used limiting dilution analyses to demonstrate that T cell clones specific for virus-infected syngeneic cells also kill uninfected allogeneic targets. Our report using virus-specific tetramers and an intracellular cytokine assay confirmed the findings that LCMV infection led to the generation of virus-specific CD8 T cells that cross-react with alloantigens, and further showed that virus-immune mice were refractory to the induction of tolerance by costimulation blockade [57]. Others have also reported that virus-immune mice are refractory to tolerance induction by costimulation blockade [53]. Because memory T cells are resistant to the induction of tolerance by costimulation blockade [107, 108], our data suggest that the allo-cross-reactive virus-specific memory T cells may precipitate the rejection of allografts even in the presence of costimulation blockade.

## 8. VIRUS INFECTION AND ESTABLISHED ALLOGRAFT SURVIVAL

Surprisingly, mice infected with LCMV one day after transplantation also exhibit shortened allograft survival [57]. Interestingly, the longer time after transplantation is, the less impact LCMV infection has on allograft survival. The deletion of alloreactive CD8<sup>+</sup> T cells is thought to be complete at this time [41, 42], making it improbable that LCMV is interfering with deletion. However, because costimulation blockade protocols are only implemented during the peritransplant period, it is possible that LCMV infection shortly after transplantation prevents the generation of regulatory T cells, which have been shown to require up to 30 days after costimulation blockade to develop [129]. Further research is necessary to elucidate the mechanisms by which LCMV shortens allograft survival during the post-transplantation timeframe.

## 9. SUMMARY

Viral infection presents a potent barrier to the induction of transplantation tolerance. In this review, we have discussed potential mechanisms by which viral infection modulates organ allograft survival in the setting of transplantation tolerance. We have briefly summarized data on three mechanisms by which viral infection may mediate these effects: bystander activation, modulation of Tregs, or heterologous immunity. Recognition of viruses by pattern recognition receptors on innate immune cells can also directly stimulate the maturation of APCs, and thus may lead to bystander activation and licensing of alloreactive T cells. Activation of APCs by viruses may trigger the release of cytokines such as IL-6 that can prevent the generation and/or function of regulatory T cells that are essential for transplantation tolerance. Finally, heterologous immunity may be responsible for the discrepancy that has been encountered when tolerance strategies that work in specific pathogen-free rodent models fail when translated to nonhuman primates and to humans [130], which have been exposed to a variety of pathogens

and thus have large memory T cell pools. Understanding the cellular and molecular mechanisms by which viruses and other microbial organisms modulate transplantation tolerance may lead to novel approaches that improve the efficacy of allogeneic organ transplantation.

## ABBREVIATIONS

APC:	Antigen presenting cell
BMT:	Bone marrow transplantation
CARD:	Caspase recruitment domain
CARDIF:	CARD adaptor inducing IFN- $\beta$
cDC:	Conventional dendritic cell
CTL:	Cytotoxic T lymphocytes
DC:	Dendritic cell
DAI:	DNA-dependent activator of IFN-regulatory factors
dsRNA:	Double stranded RNA
DST:	Donor-specific transfusion
GP:	Glycoprotein
GVHD:	Graft-versus-host disease
IFN:	Interferon
IKK:	I $\kappa$ B kinase
IKK-I:	Inducible I $\kappa$ B kinase
IPS-1:	Interferon- $\beta$ promoter stimulator
IRAK:	IL-1 receptor-associated kinase
IRF:	Interferon regulatory factory
ISRE:	Interferon-stimulated response element
LCMV:	Lymphocytic choriomeningitis virus
mAb:	Monoclonal antibody
MAVS:	Mitochondrial antiviral signaling protein
MDA5:	Melanoma differentiation factor-5
MCMV:	Murine cytomegalovirus
MyD88:	Myeloid differentiation primary response gene-88
NP:	Nucleoprotein
OPN:	Osteopontin
PRR:	Pattern recognition receptor
PV:	Pichinde virus
RIG-I:	Retinoic acid inducible gene I
RLR:	RIG-I-like receptor
pDC:	Plasmacytoid dendritic cell
TBK-1:	TANK-binding kinase 1
TCR:	T cell receptor
TIR:	Toll/interleukin-1 receptor
TLR:	Toll-line receptor
TRAF:	Tumor necrosis factor receptor-associated factor
Treg:	Regulatory T cell
TRIF:	TIR-domain-containing adaptor protein inducing IFN- $\beta$
VISA:	Virus-induced signaling adaptor
VV:	Vaccinia virus
WBI:	Whole-body irradiation

## ACKNOWLEDGMENTS

This work is supported in part by the National Institutes of Health Research Grant no. AI42669, the American Diabetes

Association Grant no. 7-05-PST-02, the Juvenile Diabetes Research Foundation, and a Diabetes Endocrinology Center Research Grant DK32520 from the National Institutes of Health. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. D. M. Miller and T. B. Thornley contributed equally to this work.

## REFERENCES

- [1] J. P. Merrill, J. E. Murray, J. H. Harrison, and W. R. Guild, "Successful homotransplantation of the human kidney between identical twins," *The Journal of the American Medical Association*, vol. 160, no. 4, pp. 277–282, 1956.
- [2] J. P. Merrill, J. E. Murray, J. H. Harrison, and W. R. Guild, "Landmark article Jan 28, 1956: successful homotransplantation of the human kidney between identical twins. By John P. Merrill, Joseph E. Murray, J. Hartwell Harrison, and Warren R. Guild," *The Journal of the American Medical Association*, vol. 251, no. 19, pp. 2566–2571, 1984.
- [3] J. P. Merrill, "Transplantation immunology 1957–1975," *Annales d'Immunologie*, vol. 129, no. 2-3, pp. 347–352, 1978.
- [4] V. Q. Habwe, "Posttransplantation quality of life: more than graft function," *American Journal of Kidney Diseases*, vol. 47, no. 4, supplement 2, pp. S98–S110, 2006.
- [5] D. Cantarovich, F. Vistoli, and J.-P. Soulillou, "Immunosuppression minimization in kidney transplantation," *Frontiers in Bioscience*, vol. 13, no. 4, pp. 1413–1432, 2008.
- [6] C. Ferry and G. Socié, "Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned?" *Experimental Hematology*, vol. 31, no. 12, pp. 1182–1186, 2003.
- [7] J. Soulillou and M. Giral, "Controlling the incidence of infection and malignancy by modifying immunosuppression," *Transplantation*, vol. 72, supplement 12, pp. S89–S93, 2001.
- [8] K. Laederach-Hofmann and B. Bunzel, "Noncompliance in organ transplant recipients: a literature review," *General Hospital Psychiatry*, vol. 22, no. 6, pp. 412–424, 2000.
- [9] L. C. Paul, "Immunobiology of chronic renal transplant rejection," *Blood Purification*, vol. 13, no. 3-4, pp. 206–218, 1995.
- [10] H. A. Kreis and C. Ponticelli, "Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors," *Transplantation*, vol. 71, supplement 11, pp. SS5–SS9, 2001.
- [11] M. Kamoun, "Mechanisms of chronic allograft dysfunction," *Therapeutic Drug Monitoring*, vol. 28, no. 1, pp. 14–18, 2006.
- [12] A. A. Rossini, D. L. Greiner, and J. P. Mordes, "Induction of immunologic tolerance for transplantation," *Physiological Reviews*, vol. 79, no. 1, pp. 99–141, 1999.
- [13] R. E. Billingham, L. Brent, and P. B. Medawar, "Actively acquired tolerance" of foreign cells," *Nature*, vol. 172, no. 4379, pp. 603–606, 1953.
- [14] R. D. Owen, "Immunogenetic consequences of vascular anastomoses between bovine twins," *Science*, vol. 102, no. 2651, pp. 400–401, 1945.
- [15] F. Burnet and F. Fenner, *The Production of Antibodies*, MacMillan, Melbourne, Australia, 1949.
- [16] J. M. Main and R. T. Prehn, "Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow," *Journal of the National Cancer Institute*, vol. 15, no. 4, pp. 1023–1029, 1955.
- [17] T. Wekerle, J. Kurtz, H. Ito, et al., "Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment," *Nature Medicine*, vol. 6, no. 4, pp. 464–469, 2000.
- [18] E. Seung, J. P. Mordes, A. A. Rossini, and D. L. Greiner, "Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning," *Journal of Clinical Investigation*, vol. 112, no. 5, pp. 795–808, 2003.
- [19] M. M. Durham, A. W. Bingaman, A. B. Adams, et al., "Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning," *The Journal of Immunology*, vol. 165, no. 1, pp. 1–4, 2000.
- [20] Y. Sharabi and D. H. Sachs, "Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen," *The Journal of Experimental Medicine*, vol. 169, no. 2, pp. 493–502, 1989.
- [21] J. D. Scandling, S. Busque, S. Dejbakhsh-Jones, et al., "Tolerance and chimerism after renal and hematopoietic-cell transplantation," *The New England Journal of Medicine*, vol. 358, no. 4, pp. 362–368, 2008.
- [22] T. Kawai, A. B. Cosimi, T. R. Spitzer, et al., "HLA-mismatched renal transplantation without maintenance immunosuppression," *The New England Journal of Medicine*, vol. 358, no. 4, pp. 353–361, 2008.
- [23] C. P. Larsen, S. J. Knechtle, A. Adams, T. Pearson, and A. D. Kirk, "A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression," *American Journal of Transplantation*, vol. 6, no. 5, part 1, pp. 876–883, 2006.
- [24] M. F. Mescher, J. M. Curtsinger, P. Agarwal, et al., "Signals required for programming effector and memory development by CD8<sup>+</sup> T cells," *Immunological Reviews*, vol. 211, no. 1, pp. 81–92, 2006.
- [25] R. Snanoudj, H. de Préneuf, C. Créput, et al., "Costimulation blockade and its possible future use in clinical transplantation," *Transplant International*, vol. 19, no. 9, pp. 693–704, 2006.
- [26] R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, "The B7 family revisited," *Annual Review of Immunology*, vol. 23, pp. 515–548, 2005.
- [27] R. H. Schwartz, "T cell anergy," *Annual Review of Immunology*, vol. 21, pp. 305–334, 2003.
- [28] J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher, "Signal 3 availability limits the CD8 T cell response to a solid tumor," *The Journal of Immunology*, vol. 178, no. 11, pp. 6752–6760, 2007.
- [29] J. M. Curtsinger, D. C. Lins, and M. F. Mescher, "Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function," *The Journal of Experimental Medicine*, vol. 197, no. 9, pp. 1141–1151, 2003.
- [30] P. S. Ohashi, S. Oehen, K. Buerki, et al., "Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice," *Cell*, vol. 65, no. 2, pp. 305–317, 1991.
- [31] M. B. A. Oldstone, M. Nerenberg, P. Southern, J. Price, and H. Lewicki, "Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response," *Cell*, vol. 65, no. 2, pp. 319–331, 1991.



- [32] C. P. Larsen and T. C. Pearson, "The CD40 pathway in allograft rejection, acceptance, and tolerance," *Current Opinion in Immunology*, vol. 9, no. 5, pp. 641–647, 1997.
- [33] T. M. Foy, A. Aruffo, J. Bajorath, J. E. Buhmann, and R. J. Noelle, "Immune regulation by CD40 and its ligand GP39," *Annual Review of Immunology*, vol. 14, pp. 591–617, 1996.
- [34] D. C. Parker, D. L. Greiner, N. E. Phillips, et al., "Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 21, pp. 9560–9564, 1995.
- [35] C. P. Larsen, D. Z. Alexander, D. Hollenbaugh, et al., "CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway," *Transplantation*, vol. 61, no. 1, pp. 4–9, 1996.
- [36] E. A. Elster, H. Xu, D. K. Tadaki, et al., "Treatment with the humanized CD154-specific monoclonal antibody, hu5c8, prevents acute rejection of primary skin allografts in nonhuman primates," *Transplantation*, vol. 72, no. 9, pp. 1473–1478, 2001.
- [37] N. S. Kenyon, L. A. Fernandez, R. Lehmann, et al., "Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154," *Diabetes*, vol. 48, no. 7, pp. 1473–1481, 1999.
- [38] N. S. Kenyon, M. Chatzipetrou, M. Masetti, et al., "Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 14, pp. 8132–8137, 1999.
- [39] E. H. Preston, H. Xu, K. K. Dhanireddy, et al., "IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates," *American Journal of Transplantation*, vol. 5, no. 5, pp. 1032–1041, 2005.
- [40] T. G. Markees, N. E. Phillips, R. J. Noelle, et al., "Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand," *Transplantation*, vol. 64, no. 2, pp. 329–335, 1997.
- [41] N. N. Iwakoshi, T. G. Markees, N. Turgeon, et al., "Skin allograft maintenance in a new synchimeric model system of tolerance," *The Journal of Immunology*, vol. 167, no. 11, pp. 6623–6630, 2001.
- [42] N. N. Iwakoshi, J. P. Mordes, T. G. Markees, N. E. Phillips, A. A. Rossini, and D. L. Greiner, "Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8<sup>+</sup> T cells and prolonged graft survival in a CTLA4-dependent manner," *The Journal of Immunology*, vol. 164, no. 1, pp. 512–521, 2000.
- [43] D. J. Lenschow, Y. Zeng, J. R. Thistlethwaite, et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig," *Science*, vol. 257, no. 5071, pp. 789–792, 1992.
- [44] H. Lin, S. F. Bolling, P. S. Linsley, et al., "Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion," *The Journal of Experimental Medicine*, vol. 178, no. 5, pp. 1801–1806, 1993.
- [45] C. P. Larsen, E. T. Elwood, D. Z. Alexander, et al., "Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways," *Nature*, vol. 381, no. 6581, pp. 434–438, 1996.
- [46] M. Yamazaki, T. Pearson, M. A. Brehm, et al., "Different mechanisms control peripheral and central tolerance in hematopoietic chimeric mice," *American Journal of Transplantation*, vol. 7, no. 7, pp. 1710–1721, 2007.
- [47] F. H. Durie, A. Aruffo, J. Ledbetter, et al., "Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease," *Journal of Clinical Investigation*, vol. 94, no. 3, pp. 1333–1338, 1994.
- [48] O. Takeuchi and S. Akira, "Recognition of viruses by innate immunity," *Immunological Reviews*, vol. 220, no. 1, pp. 214–224, 2007.
- [49] A. Pascher, S. Proesch, J. Pratschke, et al., "Rat cytomegalovirus infection interferes with anti-CD4 mAb-(RIB 5/2) mediated tolerance and induces chronic allograft damage," *American Journal of Transplantation*, vol. 6, no. 9, pp. 2035–2045, 2006.
- [50] D. Stapler, E. D. Lee, S. A. Selvaraj, et al., "Expansion of effector memory TCR V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T cells is associated with latent infection-mediated resistance to transplantation tolerance," *The Journal of Immunology*, vol. 180, no. 5, pp. 3190–3200, 2008.
- [51] M. A. Williams, J. T. Tan, A. B. Adams, et al., "Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance," *The Journal of Immunology*, vol. 167, no. 9, pp. 4987–4995, 2001.
- [52] M. A. Williams, T. M. Onami, A. B. Adams, et al., "Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen," *The Journal of Immunology*, vol. 169, no. 10, pp. 5387–5391, 2002.
- [53] A. B. Adams, M. A. Williams, T. R. Jones, et al., "Heterologous immunity provides a potent barrier to transplantation tolerance," *Journal of Clinical Investigation*, vol. 111, no. 12, pp. 1887–1895, 2003.
- [54] M. A. Brehm, T. G. Markees, K. A. Daniels, D. L. Greiner, A. A. Rossini, and R. M. Welsh, "Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections," *The Journal of Immunology*, vol. 170, no. 8, pp. 4077–4086, 2003.
- [55] D. Forman, R. M. Welsh, T. G. Markees, et al., "Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms," *The Journal of Immunology*, vol. 168, no. 12, pp. 6047–6056, 2002.
- [56] N. A. Turgeon, N. N. Iwakoshi, N. E. Phillips, et al., "Viral infection abrogates CD8<sup>+</sup> T-cell deletion induced by costimulation blockade," *Journal of Surgical Research*, vol. 93, no. 1, pp. 63–69, 2000.
- [57] R. M. Welsh, T. G. Markees, B. A. Woda, et al., "Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody," *Journal of Virology*, vol. 74, no. 5, pp. 2210–2218, 2000.
- [58] J. Obhrai and D. R. Goldstein, "The role of toll-like receptors in solid organ transplantation," *Transplantation*, vol. 81, no. 4, pp. 497–502, 2006.
- [59] J. W. Kupiec-Weglinski and R. W. Busuttil, "Ischemia and reperfusion injury in liver transplantation," *Transplantation Proceedings*, vol. 37, no. 4, pp. 1653–1656, 2005.
- [60] L. Romics Jr., G. Szabo, J. C. Coffey, H. W. Jiang, and H. P. Redmond, "The emerging role of toll-like receptor pathways in surgical diseases," *Archives of Surgery*, vol. 141, no. 6, pp. 595–601, 2006.
- [61] S. A. Fischer, M. B. Graham, M. J. Kuehnert, et al., "Transmission of lymphocytic choriomeningitis virus by organ transplantation," *The New England Journal of Medicine*, vol. 354, no. 21, pp. 2235–2249, 2006.



- [62] G. Palacios, J. Druce, L. Du, et al., "A new arenavirus in a cluster of fatal transplant-associated diseases," *The New England Journal of Medicine*, vol. 358, no. 10, pp. 991–998, 2008.
- [63] N. A. Turgeon, N. N. Iwakoshi, W. C. Meyers, et al., "Virus infection abrogates  $cd8^+$  t cell deletion induced by donor-specific transfusion and anti-cd154 monoclonal antibody," *Current Surgery*, vol. 57, no. 5, pp. 505–506, 2000.
- [64] T. B. Thornley, M. A. Brehm, T. G. Markees, et al., "TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts," *The Journal of Immunology*, vol. 176, no. 3, pp. 1561–1570, 2006.
- [65] T. B. Thornley, N. E. Phillips, B. C. Beaudette-Zlatanova, et al., "Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance," *The Journal of Immunology*, vol. 179, no. 10, pp. 6620–6629, 2007.
- [66] L. Chen, T. Wang, P. Zhou, et al., "TLR engagement prevents transplantation tolerance," *American Journal of Transplantation*, vol. 6, no. 10, pp. 2282–2291, 2006.
- [67] S. M. Palmer, L. H. Burch, R. D. Davis, et al., "The role of innate immunity in acute allograft rejection after lung transplantation," *American Journal of Respiratory and Critical Care Medicine*, vol. 168, no. 6, pp. 628–632, 2003.
- [68] E. Y. Kim and H.-S. Teh, "TNF type 2 receptor (p75) lowers the threshold of T cell activation," *The Journal of Immunology*, vol. 167, no. 12, pp. 6812–6820, 2001.
- [69] E. Y. Kim and H.-S. Teh, "Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28," *The Journal of Immunology*, vol. 173, no. 7, pp. 4500–4509, 2004.
- [70] J. M. Curtsinger, J. O. Valenzuela, P. Agarwal, D. Lins, and M. F. Mescher, "Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation," *The Journal of Immunology*, vol. 174, no. 8, pp. 4465–4469, 2005.
- [71] L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, "Recognition of double-stranded RNA and activation of NF- $\kappa$ B by Toll-like receptor 3," *Nature*, vol. 413, no. 6857, pp. 732–738, 2001.
- [72] M. Yoneyama, M. Kikuchi, T. Natsukawa, et al., "The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses," *Nature Immunology*, vol. 5, no. 7, pp. 730–737, 2004.
- [73] D.-C. Kang, R. V. Gopalkrishnan, Q. Wu, E. Jankowsky, A. M. Pyle, and P. B. Fisher, "mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 2, pp. 637–642, 2002.
- [74] L. R. Saunders and G. N. Barber, "The dsRNA binding protein family: critical roles, diverse cellular functions," *The FASEB Journal*, vol. 17, no. 9, pp. 961–983, 2003.
- [75] J.-E. Gottenberg and G. Chiocchia, "Dendritic cells and interferon-mediated autoimmunity," *Biochimie*, vol. 89, no. 6–7, pp. 856–871, 2007.
- [76] A. Pichlmair and C. Reis e Sousa, "Innate recognition of viruses," *Immunity*, vol. 27, no. 3, pp. 370–383, 2007.
- [77] D. B. Stetson and R. Medzhitov, "Type I interferons in host defense," *Immunity*, vol. 25, no. 3, pp. 373–381, 2006.
- [78] E. A. Kurt-Jones, L. Popova, L. Kwinn, et al., "Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus," *Nature Immunology*, vol. 1, no. 5, pp. 398–401, 2000.
- [79] T. Kawai, K. Takahashi, S. Sato, et al., "IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction," *Nature Immunology*, vol. 6, no. 10, pp. 981–988, 2005.
- [80] E. Meylan, J. Curran, K. Hofmann, et al., "Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus," *Nature*, vol. 437, no. 7062, pp. 1167–1172, 2005.
- [81] R. B. Seth, L. Sun, C.-K. Ea, and Z. J. Chen, "Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF- $\kappa$ B and IRF3," *Cell*, vol. 122, no. 5, pp. 669–682, 2005.
- [82] L.-G. Xu, Y.-Y. Wang, K.-J. Han, L.-Y. Li, Z. Zhai, and H.-B. Shu, "VISA is an adapter protein required for virus-triggered IFN- $\beta$  signaling," *Molecular Cell*, vol. 19, no. 6, pp. 727–740, 2005.
- [83] Q. Sun, L. Sun, H.-H. Liu, et al., "The specific and essential role of MAVS in antiviral innate immune responses," *Immunity*, vol. 24, no. 5, pp. 633–642, 2006.
- [84] K. A. Fitzgerald, S. M. McWhirter, K. L. Faia, et al., "IKK $\epsilon$  and TBK1 are essential components of the IRF3 signaling pathway," *Nature Immunology*, vol. 4, pp. 491–496, 2003.
- [85] S. Sharma, B. R. TenOever, N. Grandvaux, G.-P. Zhou, R. Lin, and J. Hiscott, "Triggering the interferon antiviral response through an IKK-related pathway," *Science*, vol. 300, no. 5622, pp. 1148–1151, 2003.
- [86] H. Kumar, T. Kawai, H. Kato, et al., "Essential role of IPS-1 in innate immune responses against RNA viruses," *The Journal of Experimental Medicine*, vol. 203, no. 7, pp. 1795–1803, 2006.
- [87] G. Oganessian, S. K. Saha, B. Guo, et al., "Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response," *Nature*, vol. 439, no. 7073, pp. 208–211, 2006.
- [88] H. Häcker, V. Redecke, B. Blagojev, et al., "Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6," *Nature*, vol. 439, no. 7073, pp. 204–207, 2006.
- [89] K. Honda, H. Yanai, H. Negishi, et al., "IRF-7 is the master regulator of type-I interferon-dependent immune responses," *Nature*, vol. 434, no. 7034, pp. 772–777, 2005.
- [90] K. Honda and T. Taniguchi, "IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors," *Nature Reviews Immunology*, vol. 6, no. 9, pp. 644–658, 2006.
- [91] K. J. Ishii, C. Coban, H. Kato, et al., "A toll-like receptor-independent antiviral response induced by double-stranded B-form DNA," *Nature Immunology*, vol. 7, no. 1, pp. 40–48, 2006.
- [92] D. B. Stetson and R. Medzhitov, "Recognition of cytosolic DNA activates an IRF3-dependent innate immune response," *Immunity*, vol. 24, no. 1, pp. 93–103, 2006.
- [93] Y. Okabe, K. Kawane, S. Akira, T. Taniguchi, and S. Nagata, "Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation," *The Journal of Experimental Medicine*, vol. 202, no. 10, pp. 1333–1339, 2005.
- [94] A. Takaoka, Z. Wang, M. K. Choi, et al., "DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response," *Nature*, vol. 448, no. 7152, pp. 501–505, 2007.
- [95] F. Heil, H. Hemmi, H. Hochrein, et al., "Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8," *Science*, vol. 303, no. 5663, pp. 1526–1529, 2004.

- [96] S. S. Diebold, T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa, "Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA," *Science*, vol. 303, no. 5663, pp. 1529–1531, 2004.
- [97] H. Hemmi, O. Takeuchi, T. Kawai, et al., "A Toll-like receptor recognizes bacterial DNA," *Nature*, vol. 408, no. 6813, pp. 740–745, 2000.
- [98] A. Iwasaki and R. Medzhitov, "Toll-like receptor control of the adaptive immune responses," *Nature Immunology*, vol. 5, no. 10, pp. 987–995, 2004.
- [99] C. Reis e Sousa, "Toll-like receptors and dendritic cells: for whom the bug tolls," *Seminars in Immunology*, vol. 16, no. 1, pp. 27–34, 2004.
- [100] S. Akira, S. Uematsu, and O. Takeuchi, "Pathogen recognition and innate immunity," *Cell*, vol. 124, no. 4, pp. 783–801, 2006.
- [101] H. Oshiumi, M. Matsumoto, K. Funami, T. Akazawa, and T. Seya, "TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon- $\beta$  induction," *Nature Immunology*, vol. 4, no. 2, pp. 161–167, 2003.
- [102] H. Hemmi, T. Kaisho, O. Takeuchi, et al., "Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway," *Nature Immunology*, vol. 3, no. 2, pp. 196–200, 2002.
- [103] T. Kawai, S. Sato, K. J. Ishii, et al., "Interferon- $\alpha$  induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6," *Nature Immunology*, vol. 5, no. 10, pp. 1061–1068, 2004.
- [104] S. Uematsu, S. Sato, M. Yamamoto, et al., "Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon- $\alpha$  induction," *The Journal of Experimental Medicine*, vol. 201, no. 6, pp. 915–923, 2005.
- [105] K. Hoshino, T. Sugiyama, M. Matsumoto, et al., "I $\kappa$ B kinase- $\alpha$  is critical for interferon- $\alpha$  production induced by Toll-like receptors 7 and 9," *Nature*, vol. 440, no. 7086, pp. 949–953, 2006.
- [106] M. L. Shinohara, L. Lu, J. Bu, et al., "Osteopontin expression is essential for interferon- $\alpha$  production by plasmacytoid dendritic cells," *Nature Immunology*, vol. 7, no. 5, pp. 498–506, 2006.
- [107] S. Wickham and D. J. J. Carr, "Molecular mimicry versus bystander activation: herpetic stromal keratitis," *Autoimmunity*, vol. 37, no. 5, pp. 393–397, 2004.
- [108] R. S. Fujinami, M. G. von Herrath, U. Christen, and J. L. Whitton, "Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease," *Clinical Microbiology Reviews*, vol. 19, no. 1, pp. 80–94, 2006.
- [109] L.-F. Lu, E. F. Lind, D. C. Gondek, et al., "Mast cells are essential intermediaries in regulatory T-cell tolerance," *Nature*, vol. 442, no. 7106, pp. 997–1002, 2006.
- [110] L. K. Selin, M. A. Brehm, Y. N. Naumov, et al., "Memory of mice and men: CD8<sup>+</sup> T-cell cross-reactivity and heterologous immunity," *Immunological Reviews*, vol. 211, no. 1, pp. 164–181, 2006.
- [111] B. O. Lee, L. Hartson, and T. D. Randall, "CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment," *The Journal of Experimental Medicine*, vol. 198, no. 11, pp. 1759–1764, 2003.
- [112] T. Luft, K. C. Pang, E. Thomas, et al., "Type I IFNs enhance the terminal differentiation of dendritic cells," *The Journal of Immunology*, vol. 161, no. 4, pp. 1947–1953, 1998.
- [113] A. N. Theofilopoulos, R. Baccala, B. Beutler, and D. H. Kono, "Type I interferons ( $\alpha/\beta$ ) in immunity and autoimmunity," *Annual Review of Immunology*, vol. 23, pp. 307–336, 2005.
- [114] E. M. Coccia, M. Severa, E. Giacomini, et al., "Viral infection and toll-like receptor agonists induce a differential expression of type I and  $\lambda$  interferons in humans plasmacytoid and monocyte-derived dendritic cells," *European Journal of Immunology*, vol. 34, no. 3, pp. 796–805, 2004.
- [115] T. G. Markees, N. E. Phillips, E. J. Gordon, et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4<sup>+</sup> T cells, interferon-gamma, and CTLA4," *Journal of Clinical Investigation*, vol. 101, no. 11, pp. 2446–2455, 1998.
- [116] L. Graca, K. Honey, E. Adams, S. P. Cobbold, and H. Waldmann, "Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance," *The Journal of Immunology*, vol. 165, no. 9, pp. 4783–4786, 2000.
- [117] S. J. Banuelos, T. G. Markees, N. E. Phillips, et al., "Regulation of skin and islet allograft survival in mice treated with costimulation blockade is mediated by different CD4<sup>+</sup> cell subsets and different mechanisms," *Transplantation*, vol. 78, no. 5, pp. 660–667, 2004.
- [118] D. R. Goldstein, B. M. Tesar, S. Akira, and F. G. Lakkis, "Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection," *Journal of Clinical Investigation*, vol. 111, no. 10, pp. 1571–1578, 2003.
- [119] W. E. Walker, I. W. Nasr, G. Camirand, B. M. Tesar, C. J. Booth, and D. R. Goldstein, "Absence of innate MyD88 signaling promotes inducible allograft acceptance," *The Journal of Immunology*, vol. 177, no. 8, pp. 5307–5316, 2006.
- [120] S. Zhou, E. A. Kurt-Jones, L. Mandell, et al., "MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection," *European Journal of Immunology*, vol. 35, no. 3, pp. 822–830, 2005.
- [121] E. Bettelli, Y. Carrier, W. Gao, et al., "Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells," *Nature*, vol. 441, no. 7090, pp. 235–238, 2006.
- [122] C. Pasare and R. Medzhitov, "Toll pathway-dependent blockade of CD4<sup>+</sup>CD25<sup>+</sup> T cell-mediated suppression by dendritic cells," *Science*, vol. 299, no. 5609, pp. 1033–1036, 2003.
- [123] R. M. Welsh and L. K. Selin, "No one is naive: the significance of heterologous T-cell immunity," *Nature Reviews Immunology*, vol. 2, no. 6, pp. 417–426, 2002.
- [124] L. K. Selin, M. Cornberg, M. A. Brehm, et al., "CD8 memory T cells: cross-reactivity and heterologous immunity," *Seminars in Immunology*, vol. 16, no. 5, pp. 335–347, 2004.
- [125] H. Yang and R. M. Welsh, "Induction of alloreactive cytotoxic T cells by acute virus infection of mice," *The Journal of Immunology*, vol. 136, no. 4, pp. 1186–1193, 1986.
- [126] S. R. Nahill and R. M. Welsh, "High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response," *The Journal of Experimental Medicine*, vol. 177, no. 2, pp. 317–327, 1993.
- [127] H. Yang and R. M. Welsh, "Induction of allospecific and virus-specific memory cytotoxic T cells during acute arenavirus infections," *Medical Microbiology and Immunology*, vol. 175, no. 2-3, pp. 137–139, 1986.
- [128] H. Yang, P. L. Dundon, S. R. Nahill, and R. M. Welsh, "Virus-induced polyclonal cytotoxic T lymphocyte stimulation," *The Journal of Immunology*, vol. 142, no. 5, pp. 1710–1718, 1989.

- [129] C. I. Kingsley, M. Karim, A. R. Bushell, and K. J. Wood, "CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses," *The Journal of Immunology*, vol. 168, no. 3, pp. 1080–1086, 2002.
- [130] M. O. Brook, K. J. Wood, and N. D. Jones, "The impact of memory T cells on rejection and the induction of tolerance," *Transplantation*, vol. 82, no. 1, pp. 1–9, 2006.

## Special Issue on Desmosomes and Desmosomal Cadherin Function in Skin and Heart Diseases—Advancements in Basic and Clinical Research

### Call for Papers

Desmosomes are cell adhesion structures (junctions) that are abundant in tissues exposed to mechanical stress, such as the skin and heart. In the last two decades, many inherited skin fragility syndromes (genodermatoses) and autoimmune blistering skin disorders (e.g., pemphigus diseases) have been linked either to impaired desmosome or desmosomal cadherin function. Furthermore, it has recently been shown that mutations in several desmosomal genes are linked to heart diseases. Recent advancements in our understanding of desmosomes and desmosomal cadherin function in normal development are providing new clues toward the pathophysiology of these diseases. The goal of this special issue is to provide an overview of our current understanding of the role of desmosomes and desmosomal cadherins in the normal development and diseases with particular emphasis on the function of desmosomal proteins in the epidermis and the heart. The submission of research articles, review articles, and case studies that are of particular interest to dermatologists is encouraged. Examples of topics that can be covered include, but are not limited to:

- Inherited and acquired desmosomal cadherin-mediated disease of the skin (e.g., pemphigus)
- Desmosomal cadherin defects and heart diseases
- Desmosomal cadherins and cancer
- The role of desmosomal proteins in normal epidermal development
- Desmosomal proteins in cell signaling and disease
- Desmosomal gene regulation

Before submission authors should carefully read over the journal's Author Guidelines, which are located at <http://www.hindawi.com/journals/drj/guidelines.html>. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at <http://mts.hindawi.com/> according to the following timetable:

Manuscript Due	November 1, 2009
First Round of Reviews	February 1, 2010
Publication Date	May 1, 2010

### Lead Guest Editor

**Peter J. Koch**, Charles C. Gates Regenerative Medicine and Stem Cell Biology Program, Department of Dermatology, University of Colorado Denver, Denver, CO, USA; [peter.koch@ucdenver.edu](mailto:peter.koch@ucdenver.edu)

### Guest Editors

**Eliane J. Mueller**, Department of Molecular Dermatology, Institute of Animal Pathology, University of Bern, Bern, Switzerland; [eliane.mueller@itpa.unibe.ch](mailto:eliane.mueller@itpa.unibe.ch)

**Mỹ G. Mahoney**, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA; [my.mahoney@jefferson.edu](mailto:my.mahoney@jefferson.edu)



## Special Issue on Molecular Genetic Markers in Female Reproductive Cancers

### Call for Papers

Cancer is a complex genetic disease as a result of accumulated genomic alterations which serve as the driving force in initiating tumor development and propelling tumor progression. The Darwinian evolution theory of cancer predicts that clinically detectable tumors harbor the molecular genetic changes that are causally related to uncontrolled growth, survival in dynamic microenvironment, invasion into surrounding normal tissues, and metastasis to distant organs. Various forms of genomic abnormalities have occurred in cancers, such as point mutations, DNA copy number alterations, and chromosomal rearrangements. Proto-oncogenes are typically activated by gene amplifications, gene translocations, and activating intragenic mutations, whereas tumor suppressors are inactivated by gene deletions (loss of heterozygosity or homologous deletion), inactivating intragenic mutations, and epigenetic silencing. Recent advances in molecular genomic technology and the success of human genome project have empowered investigators with new tools in analyzing cancer genome in great details and have expedited the discovery of new cancer-associated genes. Decoding the genetic history present in tumor DNA, as well as identification and characterization of molecular changes involving cancer-associated genes and the pathways they controlled, has not only shed new light on the molecular etiology of cancer, but also has promised for the development of new diagnostic markers and novel therapeutics.

In this special issue, we invite authors to present original research articles as well as timely reviews that will stimulate the continuing efforts in identifying and characterizing new biomarkers and therapeutic targets in female reproductive cancers including breast, ovarian, endometrial, and cervical cancer. Studies that evaluate mutations, bioinformatics for genome-wide data analysis, biomarkers to predict prognosis and treatment outcome, as well as preclinical and clinical studies in new therapeutic development are particularly welcome. Translational studies that focus on assessing the clinical significance of expression of biomarkers are also encouraged.

Before submission authors should carefully read over the journal's Author Guidelines, which are located at <http://www>

[hindawi.com/journals/jo/guidelines.html](http://hindawi.com/journals/jo/guidelines.html). Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at <http://mts.hindawi.com/> according to the following timetable:

Manuscript Due	June 1, 2009
First Round of Reviews	September 1, 2009
Publication Date	December 1, 2009

### Lead Guest Editor

**Tian-Li Wang**, Departments of Gynecology and Obstetrics and Oncology, and Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; [tlw@jhmi.edu](mailto:tlw@jhmi.edu)

### Guest Editors

**Ben Davidson**, Department of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello, 0310 Oslo, Norway; [ben.davidson@medisin.uio.no](mailto:ben.davidson@medisin.uio.no)

**Phillip J. Buckhaults**, Departments of Pathology and Microbiology and Immunology, The University of South Carolina School of Medicine, Columbia, SC 29203, USA; [phillip.buckhaults@uscmed.sc.edu](mailto:phillip.buckhaults@uscmed.sc.edu)

**Chiun-Sheng Huang**, Department of Medicine, National Taiwan University, Taipei 10617, Taiwan; [huangcs@ntu.edu.tw](mailto:huangcs@ntu.edu.tw)

**Gudi Poul**, Center for Hematology and Oncology, Department of Internal Medicine I, Wilhelminenspital, 1160 Vienna, Austria; [gudrunpohl@gmx.at](mailto:gudrunpohl@gmx.at)

## Special Issue on Modulation of Toll-like Receptor Signalling as a New Therapeutic Principle

### Call for Papers

The past 10 years in immunology were characterized by breakthrough progress in the field of innate immunity, especially by the definition of the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily. Toll-like receptors are pattern recognition receptors that play a predominant role for innate immunity and inflammation. After much insights into the basic signalling events, the next step will be to unravel the therapeutic potential of the modulation of different TLR/IL1R-pathways. These pathways are involved in many different pathologies, and the therapeutic interference could have a substantial clinical benefit in a variety of diseases, ranging from allergy, over atherosclerosis, to cancer.

We invite authors to present original research articles as well as review articles that will stimulate the continuing efforts in defining the role of innate immunity signalling pathways in clinical applications. We are particularly interested in manuscripts that report the clinical applications of approved or investigational TLR-modulating therapy in various fields of medicine (cardiovascular, oncology, dermatology, pneumology, etc.) with emphasis on efficacy, toxicity, response assessment, prognostic factors, and predictive markers. Reviews that summarize the results of basic research on Toll-like receptors and innate immunity receptors, or those receptors as targets in clinical trials and their future implications on treatment practice, are particularly welcome. Potential topics include but are not limited to:

- Clinical implications of innate immune signalling
- Therapeutical exploitation of signalling
- Clinical trials on innate immune signalling

Before submission authors should carefully read over the journal's Author Guidelines, which are located at <http://www.hindawi.com/journals/mi/guidelines.html>. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at <http://mts.hindawi.com/> according to the following timetable:

Manuscript Due	December 1, 2009
First Round of Reviews	March 1, 2010
Publication Date	June 1, 2010

### Lead Guest Editor

**Philipp M. Lepper**, Department of Pneumology, University Hospital of Bern, 3010 Bern, Switzerland; [philipp.lepper@gmx.de](mailto:philipp.lepper@gmx.de)

### Guest Editors

**Natalija Novak**, Department of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany; [natalija.novak@ukb.uni-bonn.de](mailto:natalija.novak@ukb.uni-bonn.de)

**Kathy Triantafilou**, Department of Biochemistry, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK; [k.triantafilou@sussex.ac.uk](mailto:k.triantafilou@sussex.ac.uk)

**Martha Triantafilou**, Department of Biochemistry, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK; [m.triantafilou@sussex.ac.uk](mailto:m.triantafilou@sussex.ac.uk)

**Luke A. O'Neill**, School of Biochemistry and Immunology, Trinity College Dublin, Ireland; [laoneill@tcd.ie](mailto:laoneill@tcd.ie)

**Andrew Parker**, Opsona Therapeutics Ltd., The Trinity Centre for Health Sciences, Institute of Molecular Medicine, St. James's Hospital, Dublin, Ireland; [aparker@opsona.com](mailto:aparker@opsona.com)

**Hermann Wagner**, Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany; [h.wagner@irz.tum.de](mailto:h.wagner@irz.tum.de)